Patient Reported Outcomes in Renal Transplant Patients Tolerating Gastrointestinal (GI) Symptoms Converted to Myfortic (EC-MPS)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2008 by Foothills Medical Centre.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborator:
Novartis
Information provided by:
Foothills Medical Centre
ClinicalTrials.gov Identifier:
NCT00676221
First received: May 8, 2008
Last updated: May 14, 2008
Last verified: May 2008

May 8, 2008
May 14, 2008
July 2006
August 2008   (final data collection date for primary outcome measure)
To determine the incidence of GI related symptoms (GSRS) and the health related quality of life (GIQLI) of renal transplant recipients who are currently tolerating or willing to tolerate MMF. [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00676221 on ClinicalTrials.gov Archive Site
  • To determine the impact on GI symptoms and the health related quality of life of renal transplant patients converted from MMF to EC-MPS. [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Adverse events. [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]
  • Renal function as determined by Cockroft-Gault equation. [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]
  • Routine hematological and biochemical bloodwork changes. [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Patient Reported Outcomes in Renal Transplant Patients Tolerating Gastrointestinal (GI) Symptoms Converted to Myfortic (EC-MPS)
Patient Reported Outcomes in Renal Transplant Patients Tolerating GI Symptoms Converted to Myfortic (EC-MPS).

Hypothesis: Presently, some patients' mycophenolate mofetil (MMF.,Cellcept) related gastrointestinal (GI) symptoms are not being spontaneously reported. It is postulated that a conversion to enteric-coated mycophenolate sodium (EC-MPS.,Myfortic) from MMF will reduce the objectively measured GI symptom burden and improve GI-related quality of life.

Primary Objective: To determine the incidence of GI-related symptoms and the health related quality of life of renal transplant patients that are currently tolerating MMF. Assessed by GSRS and GIQLI.

Secondary Objective: To determine the impact on GI symptoms and the health related quality of life of renal transplant patients converted from MMF to Myfortic. Assessed by GSRS and GIQLI.

Investigator originated proposal. Single centre-Foothills Medical Centre, Southern Alberta Transplant Program.

Study design: Three month, longitudinal, open-label, single arm study. Number of study visits: 3 (Baseline, 4-6 weeks, 12 weeks)

Planned sample size :Approx. 110 subjects. Study population will be primary or secondary renal transplant recipients who are stable and are on maintenance immunosuppressive medication which includes MMF.

Gastrointestinal rating scale (GSRS) and Gastrointestinal Quality of Life Index (GIQLI)will be the evaluation tool for GI symptoms, completed by study subject via a "touch screen" pc. at baseline, 4-6 week and final 12 week visit.

Study subjects will discontinue MMF following the evening dose on the day of Baseline visit and commence EC-MPS at equimolar doses of subject's current MMF dose.

At Final study visit (Week 12) study subject will be given the option of continuing on EC-MPS or resuming MMF.

Endpoints:

Primary: Incidence of patients tolerating MMF related GI symptoms.

Secondary:

  1. Patient reported symptoms and quality of life after conversion from MMF to EC-MPS.
  2. Adverse events.
  3. Renal function as determined by Cockroft-Gault equation
  4. Routine hematological and chemistry bloodwork.

Statistical consideration: Descriptive, pair T-Test analysis.

Interventional
Phase 4
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Kidney Transplant
Drug: Myfortic

Mycophenolate Mofetil (Cellcept) discontinued at Baseline visit. Mycophenolate Sodium(Myfortic)commenced the following day at equimolar doses orally BID.

Cellcept 1000mg bid = Myfortic 720mg bid

Other Names:
  • Myfortic
  • EC-MPS
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
110
September 2008
August 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Stable primary or secondary renal transplant recipients, males and females. 18-75 years of age.
  • Stable GFR (>30ml/min) Cockroft-Gault equation at time of last clinic visit and at Screening/Baseline visit.
  • Immunosuppression drug regimen that includes MMF(Cellcept)for at least 4 weeks prior to study enrollment.
  • Renal transplant recipients who are tolerating or willing to tolerate GI symptoms related to MMF.
  • Patients willing and capable of given written informed consent for study participation.

Exclusion Criteria:

  • Non-stable renal transplant recipients ( infection, thrombocytopenia,neutropenia, anemia, fluctuating GFR, acute rejection < 1 week prior to study enrollment etc.)
  • Malignancies other than treated basal cell and squamous cell carcinoma of the skin.
  • Other serious medical conditions ( uncontrolled diabetes, peptic ulcers, etc)
  • GI symptoms not related to MMF (ie infectious diarrhoea)
  • Women of childbearing potential who are unwilling to use effective means of contraception.
  • Presence of psychiatric illness that would interfere with study requ1rements.
  • Ongoing acute medical intervention or hospitalization.
  • Patients receiving any investigational drug or having received any investigational drug within 30 days prior to study entry.
Both
18 Years to 75 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Canada
 
NCT00676221
E-20097
No
Serdar Yilmaz MD., PhD., FACS. Regional Chief, Div. of Transplant Surgery, Foothills Medical Centre, Div. of Transplant Surgery
Foothills Medical Centre
Novartis
Principal Investigator: Serdar Yilmaz, MD., PhD Foothills Medical Centre, Div. of Transplant Surgery
Foothills Medical Centre
May 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP